Should we be utilizing prophylactic G-CSF in our patients with intermediate risk of febrile neutropenia due to the COVID-19 pandemic?
Are you placing more weight on patient risk factors such as age >65 or co-morbidities?
Community PollStarted
Do you recommend prophylactic G-CSF in patients with an intermediate risk of febrile neutropenia due to the COVID-19 pandemic?
19 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Pediatric Hematology/Oncology · UMass Memorial Medical Center
Answered on
There are many functions of G-CSF, including repression of T-cell and NK cell function. Unless you are certain that growth factors are not modifying the immune network to the detriment of viral clearance—there is no data that growth factors help clear viral infections.
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · University of Virginia
Answered on
In what is obviously an answer without data, my approach would be to consider the use of wbc growth factor based upon the risk of the therapy being administered and its clinical setting (as we have historically done) without attempting to factor in the "risk" of another viral illness, as we have not...
Join for free or sign in to see the full answer